ARUP institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.
BMC Nephrol. 2009 Nov 17;10:38. doi: 10.1186/1471-2369-10-38.
Alport syndrome (AS) is a progressive renal disease with cochlear and ocular involvement. The majority of AS cases are X-linked (XLAS) and due to mutations in the COL4A5 gene. Although the disease may appear early in life and progress to end stage renal disease (ESRD) in young adults, in other families ESRD occurs in middle age. Few of the more than four hundred mutations described in COL4A5 are associated with adult type XLAS, but the families may be very large.
We classified adult type AS mutation by prevalence in the US and we developed a molecular assay using a set of hybridization probes that identify the three most common adult type XLAS mutations; C1564S, L1649R, and R1677Q.
The test was validated on samples previously determined to contain one or none of these mutations. In the US, the test's clinical specificity and sensitivity are estimated to be higher than 99% and 75% respectively. Analytical specificity and sensitivity are above 99%.
This test may be useful for presymptomatic and carrier testing in families with one of the mutations and in the diagnosis of unexplained hematuria or chronic kidney disease.
Alport 综合征(AS)是一种进行性肾脏疾病,伴有耳蜗和眼部受累。大多数 AS 病例为 X 连锁(XLAS),是由于 COL4A5 基因突变引起的。尽管该疾病可能在生命早期出现,并在年轻人中进展为终末期肾病(ESRD),但在其他家族中 ESRD 发生在中年。COL4A5 中描述的四百多种突变中,只有少数与成人型 XLAS 相关,但这些家族可能非常庞大。
我们根据美国的流行情况对成人型 AS 突变进行分类,并开发了一种分子检测方法,使用一组杂交探针来鉴定三种最常见的成人型 XLAS 突变:C1564S、L1649R 和 R1677Q。
该检测方法在先前确定含有这些突变之一或无突变的样本中进行了验证。在美国,该检测的临床特异性和敏感性估计分别高于 99%和 75%。分析特异性和敏感性均高于 99%。
该检测方法可用于携带突变的家族的症状前和携带者检测,以及不明原因血尿或慢性肾病的诊断。